Pfizer: FDA approves rare blood cancer treatment.

(CercleFinance.com) - The US Food and Drug Administration on Thursday approved a drug developed by Pfizer to treat a rare blood cancer that may be fatal within a matter of months.


The drug, Besponsa, chemically known as "inotuzumab ozogamicin", is designed to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The product was reviewed and approved under the FDA's breakthrough therapy designation and priority review programs.

Copyright (c) 2017 CercleFinance.com. All rights reserved.